A Phase 1 Study of BI 3706674 in People With Gastric and Esophageal Cancers


Full Title

Open-Label Dose-Finding Trial to Explore Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BI 3706674 Given Orally as Monotherapy in Patients with Unresectable Metastatic KRAS Wild Type Amplified Gastric, Oesophageal, and Gastroesophageal-Junction Adenocarcinoma


Researchers in this study want to find the best dose of BI 3706674 to use in people with stomach or esophagus cancers. The people in this study have cancers that have kept growing or spread after treatment and contain amplification (too many copies) of a gene called KRAS. This gene can cause cancer cells to grow.

BI 3706674 blocks a protein that fuels the growth of cancer cells with KRAS amplifications. By blocking this protein, BI 3706674 may help slow or stop the growth of your cancer. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have cancer of the stomach, esophagus, or junction between the stomach and esophagus that has grown or spread after treatment.
  • Have cancer with a KRAS mutation or amplification.
  • Have recovered from the serious side effects of prior cancer therapies before taking BI 3706674.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Steven Maron’s office at 646-888-6780.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID